Vertex Pharmaceuticals reported the company’s Phase II proof-of-concept trial of VX-147 in patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS), with the drug hitting a statistically significant and clinically meaningful decrease of 47.6% in the urine protein to creatinine ratio (UPCR) at Week 13 compared to baseline. 

Retrophin is shutting down its Cambridge, Mass. offices and consolidating operations at the company’s San Diego headquarters by the end of 2017. The move is expected to result in some layoffs, the company said in a filing with the U.S. Securities and Exchange.

Retrophin Inc. said its drug to treat a rare kidney disorder was found effective in a mid-stage study.